ELEVATE: Elacestrant Combinations for the Treatment of ER+ HER2- Metastatic Breast Cancer After CDK4/6 Inhibitor
Condition: Breast Cancer
Sponsor: Stemline Therapeutics, Inc.
Protocol STML-ELA-0222: A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer
Study Treatment Arm A: Elacestrant + Alpelisib Arm B: Elacestrant + Everolimus Arm C: Elacestrant + Palbociclib Arm D: Elacestrant + Ribociclib
Eligible patients will have ER+, HER2- metastatic breast cancer that has not been treated with chemotherapy in the metastatic setting but that has progressed after up to 2 prior lines of hormonal therapy that included a CDK4/6 inhibitor. Patients in arm A (alpelisib combination arm) must also have a documented PIK3CA mutation.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.